![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ERRATUM article
Front. Oncol. , 16 April 2024
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1405306
This article is an erratum on:
Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial
An Erratum on
Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial
by Asensi-Cantó A, Rodríguez-Braun E, Beltrán-Videla A, Hurtado AM and Conesa-Zamora P (2023). Front. Oncol. 13:1238464. doi: 10.3389/fonc.2023.1238464
Due to a production error, the article type of this article mislabeled as Clinical Trial. The correct article type is Study Protocol.
The publisher apologizes for this mistake.
The original version of this article has been updated.
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: cancer, metastasis, colorectal cancer, breast cancer, imipramine, Fascin1, tumor invasion, histology
Citation: Frontiers Production Office (2024) Erratum: Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial. Front. Oncol. 14:1405306. doi: 10.3389/fonc.2024.1405306
Received: 22 March 2024; Accepted: 22 March 2024;
Published: 16 April 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.